SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq:PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced financial results for the second quarter ended June 30, 2023.
Read more at prnewswire.comPoseida Therapeutics Provides Financial Results for the Second Quarter of 2023
PR Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here